Regnum (Regnum) Days Sales Outstanding : 0.00 (As of Mar. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Regnum Days Sales Outstanding?

Regnum's average Accounts Receivable for the three months ended in Mar. 2023 was $0.00 Mil. Regnum's Revenue for the three months ended in Mar. 2023 was $0.00 Mil.

The historical rank and industry rank for Regnum's Days Sales Outstanding or its related term are showing as below:

RGMP's Days Sales Outstanding is not ranked ^*
in the Biotechnology industry.
Industry Median: 72.105
* Ranked among companies with meaningful Days Sales Outstanding only.

Regnum's Days Sales Outstanding stayed the same from Mar. 2022 (0.00) to Mar. 2023 (0.00).

Regnum Days Sales Outstanding Historical Data

The historical data trend for Regnum's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regnum Days Sales Outstanding Chart

Regnum Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Days Sales Outstanding

Get a 7-Day Free Trial

202.78

Regnum Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Days Sales Outstanding	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Regnum's Days Sales Outstanding

For the Biotechnology subindustry, Regnum's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regnum's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regnum's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Regnum's Days Sales Outstanding falls into.

Regnum Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Regnum's Days Sales Outstanding for the fiscal year that ended in Dec. 2022 is calculated as

	Days Sales Outstanding (A: Dec. 2022 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2021 )	+	Accounts Receivable (A: Dec. 2022 ))	/	count )	/	Revenue (A: Dec. 2022 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365
=	0					/	0	*	365
=	N/A

Regnum's Days Sales Outstanding for the quarter that ended in Mar. 2023 is calculated as:

	Days Sales Outstanding (Q: Mar. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Mar. 2023 ))	/	count )	/	Revenue (A: Mar. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365 / 4
=	0					/	0	*	365 / 4
=	N/A

Regnum (OTCPK:RGMP) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Regnum Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Regnum's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Regnum (Regnum) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regnum Corp (OTCPK:RGMP) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

600 Third Avenue, 19th Floor, New York, NY, USA, 10016

Website

https://www.regnumcorp.com

Regnum Corp is focused on developing and commercializing therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a CCR5 antagonist to treat multi-drug resistant HIV infection.

Regnum (Regnum) Headlines

No Headlines